Member Info for JohnnyB1

WeTookPelham. Sorry Kathryn Vatt

Scancell posted a link on LinkedIn yesterday to the Melanoma Patient Conference, Birmingham 27 to 28 February'25. This link has been given a "Heart" sign by K V.

About this lady:-

"With over 25 years of expertise in patent prosecution and examination, I have dedicated my career to becoming a Patent Subject Matter Expert, specializing in intellectual property strategy. My extensive experience spans both public and private sectors, providing comprehensive consulting that drives innovation and secures IP assets."

"My core mission is to skillfully navigate complex patent landscapes, ensuring organizations stay at the cutting edge of innovation protection. By leveraging my deep knowledge and strategic insights, I empower inventors and companies to safeguard their creations, fostering an environment where innovation thrives and achieves commercial success."

It is way above my pay grade, so I might be talking nonsense here.

I refer to the RNS 25 October 2022 "Scancell signs Commercial License Agreement with Genmab"; this states "Genmab has been granted the exclusive right to develop and commercialise the Scancell antibody in multiple novel potential therapeutic products for any and all potential disease areas, excluding cell therapy applications".

At the time I seem to recall that we were told that Genmab wasn't interested in cell therapy applications. Perhaps the truth is Scancell are interested in cell therapy applications?

C7

My very best wishes to you.

Hi Violin, Thank you for that I appreciate it.

This looks interesting, but I can't open the whole link.

"CMO Tahamtan Ahmadi explained Genmab hopes to do a deal in 2025 like its ProfoundBio acquisition in 2024 as the company seeks to develop more antibodies entirely on its own."

https://insights.citeline.com/in-vivo/growth/genmab-has-first-wholly-owned-antibodies-in-phase-iii-hunts-for-more-LJYJC6LBWNDK3LZAII4CVDVYCQ/

This is an update from the Modi patient posted on the Macmillan site yesterday:-

"I had my first CT scan after I stopped treatment on 17/01/25 and today I popped in to WGH Edinburgh to check-in with M.

It seems I've forgotten all my treatment management tricks. I wore a (new) top with tight fitting sleeves and a long sleeved thermo (I am always cold). I had to wear a gown for the first scan ever. I came off the cycle path a junction too early on the way there, and a junction too late on the way back! I must have never been for 3:15pm either because the trains there didn't fit very well.

Radiology was a bit confused because I am still regarded as being on the trial, even though treatment has stopped. They didn't know where to send the results and my onco chased and was able to get a verbal update on the phone.

The kidney tumour is still 23mm, same as when I stopped treatment. Next scan in 6 months. In year 4 we go to annual scans and (I can't remember when) subsequently we say our goodbyes.

We had a bit of a chat about trials. We don't know what interesting trend my stats followed. But they may use my data in future trials (and I wouldn't know about it) because they frequently need data from "good responders" for research projects.

We took some bloods as a final check and M will give me a phone with the results and post the scan report to me. I am in Scotland so there's no log-in-to-your-own-NHS-records here, yet.

All-in-all nothing much to say."

I've had enough of these downward inflection points; an upward inflection point would be a welcome change.

I wonder when will get an update on the progress of the first antibody deal with Genmab. At the AGM Lindy said that they were expecting an update in January, she then corrected herself and said December (2024). Hopefully no news is good news.

Sorry the numbers of shares are mixed in with the year (I left a gap when I typed it).

Another 875,000 delayed trade has gone through.

Looking at the just the bigger “unknown” trades (400k and over) on this site over the past 6 days, these total 15,622,517 shares.

If it is Calculus Capital selling they must be nearly done by now. This is a list of their declining holding over the last couple of years:-

28 September’22 40,560,345

18 May’23 37,546,331

26 October’23 34,039,009

28 August’24 27,372,187 (For some unknown reason the Holdings in Company RNS was not issued till 24 October’24).

Good find Cleaner. Not just Heather Shaw but also Miranda Payne and Pippa Corrie are attending. All 3 are on the Scope Clinical Advisory Board.

https://scancell.co.uk/pipeline/

It looks like the Announcement of the Result of the Placing should be given today. The RNS states:-

"The Bookbuild will open with immediate effect following this Announcement and is expected to close on or before 5 December 2024. The timing for the close of the Bookbuild, the number of Placing Shares to be issued and allocation of the Placing Shares shall be at the discretion of the Company in consultation with the Joint Bookrunners. The result of the Placing will be announced as soon as practicable after the close of the Bookbuild."

Under a discussion “Phase 1 trials” the same patient made the following comment 3 days ago:-

I was on a phase 1/2 trial from June 23 - June 24.

I had my drugs in a separate room adjacent to the "usual" day unit and it was a different ambience. The day unit was packed, noisy, lots of waiting and regular emergencies. The trials unit had only 7 chairs, there was hardly anyone there, no waits and it felt like a private appointment. I never saw an emergency when I was there, but lots of consultants came in and lots of talking with their patients. But the setup was the same as a day unit with chairs, curtains, normal day centre furniture, the tea and lunch trollies with cheery volunteers. At the start of my treatment in Jan 2022 I craved a cancer buddy, but it just didn't happen due to cycles not synching. As time went on, I craved a buddy less and less. I got used to my situation.

I got to know the staff better in the trial area as there was only 4 of them. It was more relaxed.

I'm not really understanding the environment you describe. It does sound different.

I was fortunate with my trial. I tolerated it fine, my results showed a trend the trial was anticipating, and it had the desired effect to manage the cancer. Just a few niggly side effects but they didn't feel like it at the time!

Edit: it was the Scancell Modi-1 (ModiFY) trial. If you google it you should find the scope on the Scancell web site. But I add this note to say it describes itself as "Modi-1 is the first candidate in Scancell’s Moditope® platform. The ModiFY study is a multicentre Phase 1 open label first-in-human clinical trial with Modi-1, an innovative cancer vaccine targeting citrullination in cancer, being administered alone or in combination with CPIs".

Bermuda,

Thank you, I was not aware of all that. I have held shares for about 3 and a half years so I do not know so much about the earlier years of Scancell. This still looks like an interesting development though.

Well worth a read and certainly all highly relevant to Scancell:-

https://www.pharmaceutical-technology.com/news/uk-life-science-startups-have-trouble-scaling-up-says-lord-vallance/

“The UK Government is also developing an industrial strategy, said Lord Vallance. This suggests a long-term, strategic focus on supporting the life sciences sector.”

British Business Bank CEO Louis Taylor also acknowledged this scale-up challenge, adding: “We know we’re lacking in the scale-up phase – that’s going to be a big focus.”

“The British Business Bank is putting this into focus via the co-investment and direct investment capability called the Future Fund Breakthrough. The goal is to help establish life sciences as an attractive asset class for UK investors, particularly domestic pension funds, which currently have very low exposure to the sector compared to their US counterparts.”

“To further facilitate pension fund investments, Taylor mentioned that the British Business Bank will be “focusing on the UK pension funds and trying to get them involved in this sector by setting up a vehicle through which they can invest”.”

I had never heard of the British Business Bank. It is worth looking at their website:-

https://www.british-business-bank.co.uk/for-finance-providers/equity-finance/long-term-investment-technology-and-science

I am probably stating the obvious but I think it is no coincidence that today’s RNS coincides with London Life Science Week. Scancell are there in force with the CEO, CFO, CMO and Head of BD in attendance. If there are any deals to be made they can now openly discuss these up to date trial results with any interested parties.

Take a look:-

https://scancell.co.uk

Zhu Chen, Senior Vice President & Head, ADC Center of Excellence, Genmab, spoke on 6 November’24 (Day 2) at the World ADC Conference San Diego. It is page 29 of the following link:-

https://web.hansonwadegroup.com/rs/355-DOS-429/images/Full-Event-Guide-15th-World-ADC-San-Diego.pdf

“2.30 Characterizing & Forecasting Translational Success of Novel ADC Linkers

• Outlining Genmab’s approach to ADC design and pipeline

• Showcasing preclinical data for novel ADC linker-drugs

• Evaluating translational success of design concepts into clinical trials”

I wonder if one of the things she discussed was Scancell’s antibody. The reason I say this is because the wording of the above presentation fits in with the language Lindy used in an interview 4 September’24. Two minutes in to the video Lindy says:-

“Genmab basically did a deal with us about 18 months ago for one of our antibodies and they are attaching a drug and a linker and are taking that forward into an ADC”.

https://www.allpointswestpod.com/episodes/behind-the-science-ceo-of-scancell-lindy-durrant-on-the-companys-breakthrough-antibody-evaluation

“Latest data shows SCIB1 administered with Stratis has induced T cell responses in 87% of patients who have been given double CPI and showed a significant increase from baseline T cell counts with full cohort data still to be analysed.”

I realise that this is not the same as the Objective Response Rate (ORR). However, I would expect that there is a direct correlation between the two.

The AGM presentation 25 October’24 showed that 36 patients had been immunised.

The only way to get 87% out of 36 patients or less (assuming percentages of point five % and over are rounded up to the next whole %) is as follows:-

13 out of 15 (86.67%)

20 out of 23 (86.96%)

26 out of 30 (86.67%)

27 out of 31 (87.1%)

As a lay person, I do not know how T cell responses are determined but strongly suspect it is from blood tests? If this is the case Scancell could for example have blood tests results (and therefore T cell response data) on 31 patients with 27 of these showing high T cell resonses.

Scancell may simply be waiting for scan results on a small number of these 31 (in this example) patients before going public on the SCIB1 trial data.

As at 15 January’24 Calculus held 34,039,009 shares (They did not take part in the placing / open offer).

Page 25 of the 2024 year end accounts show that this figure had dropped to 30,831,721 as at 31 August’24. (Calculus therefore sold 3,207,288 shares during this period):-

https://www.scancell.co.uk/Data/Sites/1/media/fininfo/2024/scancell-annual-report-2024-signed-signed.pdf

(Scancell’s website also confirms this holding as at 31 August’24).

We now have the 24 October’24 RNS advising that their holding has dropped to 27,372,187.

So Calculus must have sold a further 3,459,534 shares (30,831,721 minus 27,372,187).

I interpret from the TR-1 Form that this means this sale took place 28 August’24 and Calculus notified Scancell 30 August’24.

I suspect that this sale was to the buyer(s) who were active in August. Maybe the buyer(s) made a deal directly with Calculus?

The confusing thing to me is that the date of completion on the TR-1 states 22 October’24. Was this a clerical error by Calculus or are there circumstances when a TR-1 can be delayed? I am wondering if it is linked to something discussed on this BB in September’24 about Si trades (where details aren’t made public until later).

I see that on Friday 25 October there was a large Si trade of 125,000 at 15 pence (Put your cursor over the information next to that trade and you will see it was Si).

In September I googled Si Trades (as I had never heard of it) and came up with:-

“Under MiFID II, a systematic internaliser ("SI") is an investment firm that deals on its own account on an organised, frequent, systematic and substantial basis when executing client orders outside a regulated market, multilateral trading facility (MTF) or organised trading facility (OTF), without operating a..”

I also found the following link:-

https://www.investopedia.com/terms/m/mifid-ii.asp#:~:text=Understanding%20MiFID%20II,-MiFID%20II%20amends&text=Equities%2C%20commodities%2C%20debt%20instruments%2C,is%20located%20outside%20the%20EU.

“MiFID II limited the trading volume of a stock in a “dark pool” to 8% of the total trading volume of that stock anywhere over 12 months. Such pools are private financial exchanges for trading securities that allow institutional investors to trade large blocks of securities without any details being made public until later.”